Research programme: intron fusion proteins - Symphogen

Drug Profile

Research programme: intron fusion proteins - Symphogen

Alternative Names: Dimercept; IFP/SCAN; Intron Fusion Proteins

Latest Information Update: 13 Feb 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oregon Health & Science University; Receptor BioLogix
  • Developer Symphogen
  • Class
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Inflammation; Metabolic disorders

Most Recent Events

  • 30 Jan 2009 Symphogen acquires research programme from Receptor BioLogix
  • 19 Mar 2007 Early research is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top